Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab, Rituximab, and Methotrexate in RA-ILD
NCT07643038Phase 4Not yet recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab, rituximab in rheumatoid arthritis-associated interstitial lung disease (RA-ILD), sponsored by Chinese SLE Treatment And Research Group. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tocilizumabrituximab
03
Conditions
rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
Beyond the preview
Go deeper on NCT07643038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643038.